Niagen Bioscience (NAGE) Non-Current Assets (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Non-Current Assets of $9.2 million for Q1 2026, up 79.88% year-over-year from $5.1 million in Q1 2025, and down 4.08% quarter-over-quarter from $9.6 million in Q4 2025.
Niagen Bioscience (NAGE) Non-Current Assets (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Non-Current Assets for 14 consecutive years, with $9.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 79.88% year-over-year to $9.2 million; the TTM figure through Mar 2026 stood at $28.2 million (up 53.0% YoY), while the FY2025 annual figure was $9.6 million, up 129.89% from the prior year.
- Non-Current Assets fell to $9.2 million in Q1 2026 per NAGE's latest filing, from $9.6 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $9.6 million in Q4 2025 and bottomed at $4.2 million in Q4 2024.
- Historically, Non-Current Assets has averaged $6.4 million across 5 years, with a median of $6.3 million in 2023.
- Annual changes were most pronounced in 2024 — Non-Current Assets sank 30.37% — and 2025, when it jumped 129.89%.
- Niagen Bioscience's Non-Current Assets stood at $7.5 million in 2022, then retreated by 27.5% to $5.4 million in 2023, then retreated by 23.09% to $4.2 million in 2024, then soared by 129.89% to $9.6 million in 2025, then fell by 4.08% to $9.2 million in 2026.
- Business Quant data shows NAGE's Non-Current Assets at $9.2 million in Q1 2026, $9.6 million in Q4 2025, and $4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 8.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.80 Mn |
| Mar 31, 2026 | 9.21 Mn |
| Dec 31, 2025 | 9.60 Mn |
| Sep 30, 2025 | 4.52 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | 5.12 Mn |
| Dec 31, 2024 | 4.18 Mn |
| Sep 30, 2024 | 4.39 Mn |
| Jun 30, 2024 | 4.73 Mn |
| Mar 31, 2024 | 5.10 Mn |
| Dec 31, 2023 | 5.43 Mn |
| Sep 30, 2023 | 6.30 Mn |
| Jun 30, 2023 | 6.79 Mn |
| Mar 31, 2023 | 7.20 Mn |
| Dec 31, 2022 | 7.49 Mn |
| Sep 30, 2022 | 7.76 Mn |
| Jun 30, 2022 | 8.11 Mn |
| Mar 31, 2022 | 8.41 Mn |
| Dec 31, 2021 | 8.94 Mn |
| Sep 30, 2021 | 7.62 Mn |